Scientific Programme
Scientific Programme of the Virtual CVOT Summit on 29 – 30 October 2020
Thursday, 29 October 2020
18:00 - 18:10 CET
Welcome and introductionSchnell O (Munich, Germany)
18:10 – 19:30 CET
Keynote lecturesChair: Kosiborod M (Kansas City, USA), Schnell O (Munich, Germany)
18:10 – 18:35
Cardiometabolic Center of Excellence – a model to improve guideline implementation, quality of care and outcomes in patients with Type 2 Diabetes and Cardiovascular DiseaseKosiborod M (Kansas City, USA)
18:35 – 19:00
Obesity – risk factor and treatment targetBlueher M (Leipzig, Germany)
19:00 – 19:30
Discussion
Friday, 30 October 2020
08:30 – 10:30 CET
Challenges in diabetes management – novel strategies and guidelinesChair: Standl E (Munich, Germany)
08:30 – 08:55
Diabetes mellitus in COVID 19 – risks and therapeutic strategiesForst T (Mannheim, Germany)
08:55 – 09:20
CVOT results translated into primary care diabetes guidelines and recommendations – gaps and opportunitiesCos Claramunt FX (Barcelona, Spain)
09:20 – 09:55
Primary prevention of CVD in the light of current diabetes guidelinesMathieu C (Leuven, Belgium)
09:55 – 10:15
Living guidelines: On the dynamic updating of recommendationsVandvik PO (Oslo, Norway)
10:15 – 10:30
Discussion
10:30 – 11:00 CET
Break
11:00 – 13:00 CET
Diabetes, kidney disease and heart failure: Novel outcome studies and treatment options (1)Chair: Wanner C (Wuerzburg, Germany), Groop P-H (Helsinki, Finland)
11:00 – 11:20
Unmet needs in diabetic kidney diseaseFioretto P (Padova, Italy)
11:20 – 11:40
Finerenone – outcomes in chronic kidney disease and type 2 diabetesRossing P (Copenhagen, Denmark)
10:40 – 12:00
Discussion
12:00 – 12:20
Dapa-CKD – from clinical evidence to clinical practiceHeerspink HL (Groningen, Netherlands)
12:20 – 12:40
SGLT2 inhibitors in diabetes and cardio-renal management: a class effect?Standl E (Munich, Germany)
12:40 – 13:00
Discussion
13:00 – 13:30 CET
Break
13:30 – 14:30 CET
Diabetes, kidney disease and heart failure: Novel outcome studies and treatment options (2)Chair: Giorgino F (Bari, Italy), Wanner C (Wuerzburg, Germany)
13:30 – 13:50
SGLT2 inhibitors in the prevention and treatment of heart failure: evidence from CVOTs and implicationsSattar N (Glasgow, Scotland)
13:50 – 14:00
Commentary: Novel outcomes on SGLT-2 Is: Practical ConsiderationsRodbard H (Rockville, USA)
14:00 – 14:30
Panel Discussion: Positioning of SGLT2 inhibitors and MRAs in the management of chronic diseasesAll
14:30 – 15:00 CET
Oral presentationsChair: Lehrke M (Aachen, Germany)
Implications of the initial eGFR response to SGLT2 inhibition with empagliflozin on CV and kidney outcomes: the ‘eGFR dip’ in EMPA-REG OUTCOMEKraus B et al. (Würzburg, Germany)
Very high cardiovascular risk according to 2019 ESC EASD guidelines and coronary artery calcification scoreValensi P et al. (Paris, France)
Changes of the plasma mRNA levels of some genes in patients with type 2 diabetes mellitusSaenko Y et al. (Kiev, Ukraine)
Central obesity is associated with increased risk of hospitalization or mortality due to heart failure in adults with type 1 diabetesParente E et al. (Helsinki, Finland)
15:00 – 15:30 CET
Break
15:30 - 16:15 CET
Industry panel Chair: Schnell O (Munich, Germany)
16:15 – 17:30 CET
GLP-1 receptor agonists: Update 2020Chair: Schnell O (Munich, Germany), Standl E (Munich, Germany)
16:15 – 16:35
Latest evidence on GLP-1 receptor agonists mechanism of action on the cardiovascular systemLehrke M (Aachen, Germany)
16:35 – 16:55
Heterogeneity and similarities in GLP-1RA CVOTs: focus on specific outcomesGiorgino F (Bari, Italy)
16:55 – 17:10
Commentary: Novel outcomes on GLP-1-RAs: Practical ConsiderationsGallwitz B (Tuebingen, Germany)
17:10 – 17:30
Discussion
17:30 – 17:45 CET
Abstract awards and closingSchnell O (Munich, Germany)